Patents Assigned to Oxford Biomedica (UK) Limited
-
Publication number: 20110052577Abstract: The use of an ScFv Ab (ScFv Ab) capable of recognising a disease associated molecule (DAM) in the manufacture of a medicament for the prevention and/or treatment of a disease condition associated with a DAM is described. The ScFv Ab has therapeutic, diagnostic and prognostic applications.Type: ApplicationFiled: July 28, 2010Publication date: March 3, 2011Applicant: Oxford Biomedica (UK) LimitedInventors: Alan Kingsman, Susan Mary Kingsman, Christopher Robert Bebbington, Miles William Carroll, Fiona Margaret Ellard, Kevin Alan Myers
-
Patent number: 7888115Abstract: There is provided an MHC class I peptide epitope from 5T4 antigen. In particular, there is provided a peptide epitope of 5T4 which comprises one of the following: (i) the amino acid sequence shown as SEQ ID No.2; (ii) the minimal epitope from the amino acid sequence shown as SEQ ID No.3; (iii) the minimal epitope from the amino acid sequence shown as SEQ ID No.4. (iv) the minimal epitope from the amino acid sequence shown as SEQ ID No. 5. (v) the minimal epitope from the amino acid sequence shown as SEQ ID No.6. (vi) the minimal epitope from the amino acid sequence shown as SEQ ID No.7. There is also provided a vaccine comprising such a peptide (or precursor thereof) and its use to treat and/or prevent a disease, in particular a cancerous disease.Type: GrantFiled: July 10, 2009Date of Patent: February 15, 2011Assignee: Oxford Biomedica (UK) LimitedInventors: Miles William Carroll, Susan Mary Kingsman, Irina Redchenko
-
Publication number: 20100310584Abstract: The present invention relates to a novel method for the delivery of agents to tumour cells. In particular it relates to a method for the specific delivery of agents to the interior of tumour cells. Uses of the method are also described.Type: ApplicationFiled: October 21, 2009Publication date: December 9, 2010Applicant: OXFORD BIOMEDICA (UK) LIMITEDInventors: Miles Carroll, Abigail Lamikanra, Alan Kingsman
-
Publication number: 20100158884Abstract: The invention provides the use of an enzyme and a prodrug in the manufacture of a medicament for use in inducing an anti-tumour immune response in a human patient.Type: ApplicationFiled: February 3, 2010Publication date: June 24, 2010Applicant: OXFORD BIOMEDICA (UK) LIMITEDInventors: Richard Harrop, Miles William Carroll, Susan Mary Kingsman
-
Publication number: 20100124534Abstract: The present invention provides a method of monitoring the efficacy of an immunotherapy in a mammalian subject, wherein the subject has been administered an immunotherapy, wherein the immunotherapy comprises a viral vector containing a polynucleotide encoding an antigen, wherein the viral vector is capable of transducing cells in the mammalian subject to cause the cells to express the antigen; the method comprising: (b) measuring, from a biological sample isolated from the subject, an immune response of the subject to the antigen and comparing the immune response of the subject to the antigen to a reference measurement of immune response to the antigen; (c) measuring, from a biological sample isolated from the subject, an immune response of the subject to the viral vector and comparing the immune response of the subject to the viral vector to a reference measurement of immune response to the viral vector; and (d) determining efficacy based on the comparisons of (b) and (c), wherein an elevated immune responseType: ApplicationFiled: July 15, 2009Publication date: May 20, 2010Applicant: OXFORD BIOMEDICA (UK) LIMITEDInventors: Richard Harrop, William Shingler, Stuart Naylor, Michael McDonald
-
Patent number: 7718627Abstract: A vector comprising a nucleotide sequence of interest (“NOI”) encoding a product of interest (“POI”) is described. The NOI and/or the POI is capable of recognizing a tumor, such that in use the vector is capable of delivering the NOI and/or the POI to the tumor.Type: GrantFiled: April 25, 2006Date of Patent: May 18, 2010Assignee: Oxford Biomedica (UK) LimitedInventors: Susan M. Kingsman, Christopher R. Bebbington, Fiona M. Ellard, Miles W. Carroll, Kevin A. Myers
-
Publication number: 20100086995Abstract: There is provided an MHC class I peptide epitope from 5T4 antigen. In particular, there is provided a peptide epitope of 5T4 which comprises one of the following: (i) the amino acid sequence shown as SEQ ID No.2; (ii) the minimal epitope from the amino acid sequence shown as SEQ ID No.3; (iii) the minimal epitope from the amino acid sequence shown as SEQ ID No.4. (iv) the minimal epitope from the amino acid sequence shown as SEQ ID No. 5. (v) the minimal epitope from the amino acid sequence shown as SEQ ID No.6. (vi) the minimal epitope from the amino acid sequence shown as SEQ ID No.7. There is also provided a vaccine comprising such a peptide (or precursor thereof) and its use to treat and/or prevent a disease, in particular a cancerous disease.Type: ApplicationFiled: July 10, 2009Publication date: April 8, 2010Applicant: OXFORD BIOMEDICA (UK) LIMITEDInventors: Miles Carroll, Susan Kingsman, Irina Redchenko
-
Patent number: 7666669Abstract: The present invention provides 5T4 tumour-associated antigen (TAA) for use in a method of immunotherapy of tumours. The invention also relates to a recombinant poxvirus vector from which at least one immune evasion gene has been deleted, which comprises a nucleic acid sequence encoding a 5T4 TAA and the use thereof in vaccinating against and in treating tumours.Type: GrantFiled: September 18, 2006Date of Patent: February 23, 2010Assignee: Oxford Biomedica (UK) LimitedInventors: Miles W. Carroll, Kevin A. Myers
-
Publication number: 20100040539Abstract: The use of an ScFv Ab (ScFv Ab) capable of recognising a disease associated molecule (DAM) in the manufacture of a medicament for the prevention and/or treatment of a disease condition associated with a DAM is described. The ScFv Ab has therapeutic, diagnostic and prognostic applications.Type: ApplicationFiled: May 15, 2008Publication date: February 18, 2010Applicant: OXFORD BIOMEDICA (UK) LIMITEDInventors: Alan Kingsman, Susan Mary Kingsman, Christopher Robert Bebbington, Miles William Carroll, Fiona Margaret Ellard, Kevin Alan Myers
-
Patent number: 7659383Abstract: Canine and feline 5T4 polypeptide sequences and nucleotide sequences encoding them are provided. A vector system comprising a nucleic acid encoding 5T4 and a 5T4-specific agent are also provided.Type: GrantFiled: July 8, 2008Date of Patent: February 9, 2010Assignee: Oxford Biomedica (UK) LimitedInventors: Kevin Alan Myers, Noel Drury, Miles William Carroll
-
Patent number: 7635687Abstract: The present invention provides a vector system comprising a nucleotide sequence coding for an antibody. In particular, the present invention relates to the use of such a vector system in a subject, where the nucleotide sequence is expressed in vivo to produce said antibody.Type: GrantFiled: December 30, 2002Date of Patent: December 22, 2009Assignee: Oxford Biomedica (UK) LimitedInventors: Alan John Kingsman, Christopher Robert Bebbington, Miles William Carroll, Fiona Margaret Ellard, Susan Mary Kingsman, Kevin Alan Myers, Abigail Lamikanra
-
Publication number: 20090280138Abstract: The present invention relates to peptide epitopes of 5T4 antigen and their use in immunotherapy. In particular, the present invention relates to any one of the peptide epitopes as described herein as well as their use in diagnosis and therapy of cancer.Type: ApplicationFiled: May 12, 2006Publication date: November 12, 2009Applicant: OXFORD BIOMEDICA (UK) LIMITEDInventors: Richard Harrop, William Shingler, Susan Kingsman
-
Patent number: 7615612Abstract: The present invention provides 5T4 tumour-associated antigen (TAA) for use in a method of immunotherapy of tumours. The invention also relates to a recombinant poxvirus vector from which at least one immune evasion gene has been deleted, which comprises a nucleic acid sequence encoding a 5T4 TAA and the use thereof in vaccinating against and in treating tumours.Type: GrantFiled: March 15, 2007Date of Patent: November 10, 2009Assignee: Oxford Biomedica (UK) LimitedInventors: Miles W. Carroll, Kevin A. Myers
-
Patent number: 7601698Abstract: The present invention provides 5T4 tumour-associated antigen (TAA) for use in a method of immunotherapy of tumours. The invention also relates to a recombinant poxvirus vector from which at least one immune evasion gene has been deleted, which comprises a nucleic acid sequence encoding a 5T4 TAA and the use thereof in vaccinating against and in treating tumours.Type: GrantFiled: November 22, 2005Date of Patent: October 13, 2009Assignee: Oxford Biomedica (UK) LimitedInventors: Miles W. Carroll, Kevin A. Myers
-
Patent number: 7585676Abstract: Provided herein is a retroviral vector comprising, and capable of expressing, a nucleotide of interest (NOI), wherein the NOI encodes an RNA or protein which is harmful to a cell.Type: GrantFiled: January 29, 2008Date of Patent: September 8, 2009Assignee: Oxford Biomedica (UK) LimitedInventors: Kyriacos Mitrophanous, Mary Collins, Yasuhiro Takeuchi, Yasuhiro Ikeda
-
Patent number: 7575916Abstract: There is provided an MHC class I peptide epitope from 5T4 antigen. In particular, there is provided a peptide epitope of 5T4 which comprises one of the following: (i) the amino acid sequence shown as SEQ ID No. 2; (ii) the minimal epitope from the amino acid sequence shown as SEQ ID No. 3; (iii) the minimal epitope from the amino acid sequence shown as SEQ ID No. 4. (iv) the minimal epitope from the amino acid sequence shown as SEQ ID No. 5. (v) the minimal epitope from the amino acid sequence shown as SEQ ID No. 6. (vi) the minimal epitope from the amino acid sequence shown as SEQ ID No. 7. There is also provided a vaccine comprising such a peptide (or precursor thereof) and its use to treat and/or prevent a disease, in particular a cancerous disease. There is also provided a nucleic acid molecule encoding a MHC class I peptide epitope from the human 5T4 tumor-associated antigen and vector comprising the nucleic acid molecule.Type: GrantFiled: February 13, 2003Date of Patent: August 18, 2009Assignee: Oxford Biomedica (UK) LimitedInventors: Miles Carroll, Susan Kingsman, Irina Redchenko
-
Publication number: 20090191230Abstract: The invention provides the use of an enzyme and a prodrug in the manufacture of a medicament for use in inducing an anti-tumour immune response in a human patient.Type: ApplicationFiled: July 10, 2006Publication date: July 30, 2009Applicant: Oxford Biomedica (UK) LimitedInventors: Richard Harrop, Miles W. Carroll, Susan M. Kingsman
-
Publication number: 20090155290Abstract: The present invention relates to a novel method for the delivery of agents to tumour cells. In particular it relates to a method for the specific delivery of agents to the interior of tumour cells. Uses of the method are also described.Type: ApplicationFiled: December 10, 2008Publication date: June 18, 2009Applicant: OXFORD BIOMEDICA (UK) LIMITEDInventors: Miles Carroll, Abigail Lamikanra, Alan Kingsman
-
Patent number: 7541044Abstract: The invention provides the use of an enzyme and a prodrug in the manufacture of a medicament for use in inducing an anti-tumor immune response in a human patient.Type: GrantFiled: September 29, 2006Date of Patent: June 2, 2009Assignee: Oxford Biomedica (UK) LimitedInventors: Richard Harrop, Miles Carroll, Susan Kingsman
-
Patent number: 7531648Abstract: A vector comprising a nucleotide sequence of interest (“NOI”) encoding a product of interest (“POI”) is described. The NOI and/or the POI is capable of recognizing a tumor, such that in use the vector is capable of delivering the NOI and/or the POI to the tumor.Type: GrantFiled: March 22, 2002Date of Patent: May 12, 2009Assignee: Oxford Biomedica (UK) LimitedInventors: Susan Mary Kingsman, Christopher Robert Bebbington, Fiona Margaret Ellard, Miles William Carroll, Kevin Alan Myers